Burning Rock Biotech (BNR) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Burning Rock Biotech (BNR) has outperformed Sera Prognostics (SERA) over the past year, gaining 68.4% versus a loss of 36.3%. Over five years, SERA leads with a -80.9% price change compared with -89.4% for BNR. Burning Rock Biotech is the larger company by market cap ($155.6 million vs $79.9 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNR | SERA |
|---|---|---|
| Share price | $14.76 | $2.03 |
| Market cap | $155.61M | $79.89M |
| 1-day change | -2.80% | -2.19% |
| YTD return | -24.67% | -29.83% |
| 1-year return | +68.40% | -36.31% |
| 5-year return | -89.43% | -80.92% |
| EPS (TTM) | $-0.80 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $41.72 | $3.95 |
| 52-week low | $6.79 | $1.56 |
| Distance from 52-week high | -64.63% | -48.73% |
| Average volume | 28.77K | 28.38K |
| Shares outstanding | 8.81M | 38.48M |
| Employees | 667 | — |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNR has outperformed SERA by 104.7 percentage points over the past year.
About Burning Rock Biotech
BNR stock →Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Health Care · Medical Specialities · 667 employees
BNR vs SERA FAQ
Which is bigger, Burning Rock Biotech or Sera Prognostics?
Burning Rock Biotech (BNR) is larger, with a market capitalization of $155.61M compared with $79.89M for Sera Prognostics (SERA).
Which stock has performed better over the past year, BNR or SERA?
BNR returned +68.40% over the past 12 months, compared with -36.31% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are Burning Rock Biotech and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.